Show simple item record

dc.contributor.authorNeogi, Tuhina
dc.contributor.authorAletaha, Daniel
dc.contributor.authorSilman, Alan J.
dc.contributor.authorNaden, Raymond L.
dc.contributor.authorFelson, David T.
dc.contributor.authorAggarwal, Rohit
dc.contributor.authorBingham, Clifton O. III
dc.contributor.authorBirnbaum, Neal S.
dc.contributor.authorBurmester, Gerd R.
dc.contributor.authorBykerk, Vivian P.
dc.contributor.authorCohen, Marc D.
dc.contributor.authorCombe, Bernard
dc.contributor.authorCostenbader, Karen H.
dc.contributor.authorDougados, Maxime
dc.contributor.authorEmery, Paul
dc.contributor.authorFerraccioli, Gianfranco
dc.contributor.authorHazes, Johanna M. W.
dc.contributor.authorHobbs, Kathryn
dc.contributor.authorHuizinga, Tom W. J.
dc.contributor.authorKavanaugh, Arthur
dc.contributor.authorKay, Jonathan
dc.date2022-08-11T08:10:51.000
dc.date.accessioned2022-08-23T17:22:33Z
dc.date.available2022-08-23T17:22:33Z
dc.date.issued2010-09-01
dc.date.submitted2015-04-17
dc.identifier.citationNeogi T, Aletaha D, Silman AJ, Naden RL, Felson DT, Aggarwal R, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Khanna D, Kvien TK, Laing T, Liao K, Mease P, Ménard HA, Moreland LW, Nair R, Pincus T, Ringold S, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G; American College of Rheumatology; European League Against Rheumatism. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum. 2010 Sep;62(9):2582-91. doi: 10.1002/art.27580. PubMed PMID: 20872596; PubMed Central PMCID: PMC3077961. <a href="http://dx.doi.org/10.1002/art.27580">Link to article on publisher's site</a>
dc.identifier.issn0004-3591 (Linking)
dc.identifier.doi10.1002/art.27580
dc.identifier.pmid20872596
dc.identifier.urihttp://hdl.handle.net/20.500.14038/48771
dc.description<p>Full author list omitted for brevity. For the full list of authors, see article.</p>
dc.description.abstractOBJECTIVE: The American College of Rheumatology and the European League Against Rheumatism have developed new classification criteria for rheumatoid arthritis (RA). The aim of Phase 2 of the development process was to achieve expert consensus on the clinical and laboratory variables that should contribute to the final criteria set. METHODS: Twenty-four expert RA clinicians (12 from Europe and 12 from North America) participated in Phase 2. A consensus-based decision analysis approach was used to identify factors (and their relative weights) that influence the probability of "developing RA," complemented by data from the Phase 1 study. Patient case scenarios were used to identify and reach consensus on factors important in determining the probability of RA development. Decision analytic software was used to derive the relative weights for each of the factors and their categories, using choice-based conjoint analysis. RESULTS: The expert panel agreed that the new classification criteria should be applied to individuals with undifferentiated inflammatory arthritis in whom at least 1 joint is deemed by an expert assessor to be swollen, indicating definite synovitis. In this clinical setting, they identified 4 additional criteria as being important: number of joints involved and site of involvement, serologic abnormality, acute-phase response, and duration of symptoms in the involved joints. These criteria were consistent with those identified in the Phase 1 data-driven approach. CONCLUSION: The consensus-based, decision analysis approach used in Phase 2 complemented the Phase 1 efforts. The 4 criteria and their relative weights form the basis of the final criteria set.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=20872596&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077961/
dc.subjectAcute-Phase Reaction
dc.subjectArthritis, Rheumatoid
dc.subjectClinical Chemistry Tests
dc.subjectConsensus
dc.subjectDecision Making, Computer-Assisted
dc.subjectDecision Support Techniques
dc.subjectEurope
dc.subjectEvidence-Based Medicine
dc.subjectFemale
dc.subjectHumans
dc.subjectInternational Cooperation
dc.subjectMale
dc.subjectNorth America
dc.subjectRheumatology
dc.subjectSocieties, Medical
dc.subjectSynovitis
dc.subjectTerminology as Topic
dc.subjectMusculoskeletal Diseases
dc.subjectRheumatology
dc.subjectSkin and Connective Tissue Diseases
dc.titleThe 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report
dc.typeJournal Article
dc.source.journaltitleArthritis and rheumatism
dc.source.volume62
dc.source.issue9
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/rheumatology_pubs/97
dc.identifier.contextkey7002921
html.description.abstract<p>OBJECTIVE: The American College of Rheumatology and the European League Against Rheumatism have developed new classification criteria for rheumatoid arthritis (RA). The aim of Phase 2 of the development process was to achieve expert consensus on the clinical and laboratory variables that should contribute to the final criteria set.</p> <p>METHODS: Twenty-four expert RA clinicians (12 from Europe and 12 from North America) participated in Phase 2. A consensus-based decision analysis approach was used to identify factors (and their relative weights) that influence the probability of "developing RA," complemented by data from the Phase 1 study. Patient case scenarios were used to identify and reach consensus on factors important in determining the probability of RA development. Decision analytic software was used to derive the relative weights for each of the factors and their categories, using choice-based conjoint analysis.</p> <p>RESULTS: The expert panel agreed that the new classification criteria should be applied to individuals with undifferentiated inflammatory arthritis in whom at least 1 joint is deemed by an expert assessor to be swollen, indicating definite synovitis. In this clinical setting, they identified 4 additional criteria as being important: number of joints involved and site of involvement, serologic abnormality, acute-phase response, and duration of symptoms in the involved joints. These criteria were consistent with those identified in the Phase 1 data-driven approach.</p> <p>CONCLUSION: The consensus-based, decision analysis approach used in Phase 2 complemented the Phase 1 efforts. The 4 criteria and their relative weights form the basis of the final criteria set.</p>
dc.identifier.submissionpathrheumatology_pubs/97
dc.contributor.departmentDepartment of Medicine, Division of Rheumatology
dc.source.pages2582-91


This item appears in the following Collection(s)

Show simple item record